Atazanavir & Ritonavir bulk supplier for pharma manufacturers

Atazanavir & Ritonavir Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 300 mg Atazanavir + 100 mg Ritonavir

Reference Brands: Evotaz®(US)

Atazanavir/Ritonavir Tablets (300/100 mg) are key antiretrovirals for HIV-1 treatment. Available via PharmaTradz from WHO-GMP and USFDA-approved suppliers, this fixed-dose combo ensures boosted efficacy and once-daily convenience. Ideal for global procurement, tenders, and HIV programs seeking compliant, cost-effective sourcing.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Atazanavir & Ritonavir? List it or send an offer →

Product Description:

Atazanavir & Ritonavir Tablets are a fixed-dose antiretroviral combination used in the management of HIV-1 infection, with Ritonavir boosting Atazanavir’s effectiveness. Available in a 300 mg + 100 mg formulation, this once-daily therapy is WHO-recommended and USFDA-approved. On PharmaTradz, global buyers can connect with GMP-certified manufacturers for bulk procurement of quality-assured Atazanavir/Ritonavir tablets. Ideal for hospitals, NGOs, government tenders, and HIV treatment programs, PharmaTradz simplifies sourcing of affordable, compliant ARVs. Partner with reliable suppliers to support uninterrupted access to essential HIV care in both regulated and emerging markets.

Atazanavir & Ritonavir — third party manufacturing & bulk supply

Atazanavir & Ritonavir is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Atazanavir & Ritonavir is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Atazanavir & Ritonavir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Atazanavir & Ritonavir →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Atazanavir and ritonavir are used together to treat HIV-1 infection. Atazanavir is a protease inhibitor, and ritonavir is used in a low dose to boost atazanavir levels, helping reduce viral load and improve immune function as part of combination antiretroviral therapy.

This combination is made from two antiretroviral agents: atazanavir sulfate, a protease inhibitor, and ritonavir, another protease inhibitor used as a pharmacokinetic enhancer to increase atazanavir's effectiveness.

The commonly known trade name for the fixed-dose combination is not globally standardized, but the regimen is often used clinically as “Atazanavir boosted with Ritonavir.” Atazanavir alone is branded as Reyataz.

Atazanavir (Reyataz) is manufactured by Bristol-Myers Squibb (BMS). Ritonavir (Norvir) is manufactured by AbbVie. Many generic manufacturers produce the combination for various markets.

The generic name is atazanavir and ritonavir.

While no single fixed-dose brand is universally marketed, the individual brands are Reyataz (atazanavir) and Norvir (ritonavir). In practice, the combination is referred to as atazanavir/ritonavir.

Manufacturing occurs in multiple approved facilities across the USA, Europe, and India, depending on the innovator or generic manufacturer supplying the product.